KR940007056A - 단백질과 이 단백질을 코우드하는 dna 및 이 단백질의 제조방법 - Google Patents

단백질과 이 단백질을 코우드하는 dna 및 이 단백질의 제조방법 Download PDF

Info

Publication number
KR940007056A
KR940007056A KR1019930019832A KR930019832A KR940007056A KR 940007056 A KR940007056 A KR 940007056A KR 1019930019832 A KR1019930019832 A KR 1019930019832A KR 930019832 A KR930019832 A KR 930019832A KR 940007056 A KR940007056 A KR 940007056A
Authority
KR
South Korea
Prior art keywords
ala
val
glu
leu
pro
Prior art date
Application number
KR1019930019832A
Other languages
English (en)
Other versions
KR100294977B1 (ko
Inventor
간소오 이와끼
쓰네다까 오오다
마사시 구리모도
Original Assignee
하야시바라 겐
가부시기가이샤 하야시바라 세이부쓰 가가꾸 겡규우죠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하야시바라 겐, 가부시기가이샤 하야시바라 세이부쓰 가가꾸 겡규우죠 filed Critical 하야시바라 겐
Publication of KR940007056A publication Critical patent/KR940007056A/ko
Application granted granted Critical
Publication of KR100294977B1 publication Critical patent/KR100294977B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

분자량이 45,000±5,000이고 pI가 5.7±0.5이며 암전이 억제활성을 가진 신규 단백질을 제공한다.
이 단백질은 인간 세포, 동물 세포 및 상기 단백질을 생산할 수 있는 미생물을 칼멧-계량형 소결핵균(BCG)과 리포다당(LPS)등의 유발제로 자극하면서 영양배지에서 배양하고, 그 배양 상청액으로부터 단백질을 회수하여서 되는 제조방법에 따라 제조할 수 있다.

Description

단백질과 이 단백질을 코우드하는 DNA 및 이 단백질의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 아래의 물리화학적 성질은 가진 단백질. (1) 분자량 : 45,000±5,000 (2) 등전점 : pI=5.7±0.5 (3)부분 아미노산 배열 : Asp-Ser-Glu-Gly-Tyr-Ile-Tyr-Ala-Arg-Gly-Ala-Gln-Asp-Met-Lys 또는 Gly-His-Trp-Ser-His-Asp-Pro-Phe-Glu을 가짐, (4) 용매에 대한 용해성 : 물, 생리식염수 및 인산완충액에 용해, (5) 생물활성 : 인간의 대장암 유래의 주화 배양 세포인 RPMI4788세포(FERM BP-2429)의 전이를 억제하는 활성을 가짐, (6) 안정성 : 수용액중에서 pH7.2 및 100℃에서 30분간 방치하면 실활(失活)함. 수용액중에서 pH7.2 및 4℃에서 1개월 방치하여도 안정.
  2. 제1항에 있어서, 실질적으로 아래의 화학식 1로 나타내어지는 아미노산 배열을 함유하는 단백질.
    화학식 1
    1 Met - Thr - Ser - Lys - Gly - Pro - Glu - Glu - Glu - His -
    11 Pro - Ser - Val - Thr - Leu - Phe - Arg - Gln - Tyr - Leu -
    21 Arg - Ile - Arg - Thr - Val - Gln - Pro - Lys - Pro - Asp -
    31 Tyr - Gly - Ala - Ala - Val - Ala - Phe - Phe - Glu - Glu -
    41 Thr - Ala - Arg - Gln - Leu - Gly - Leu - Gly - Cys - Gln -
    51 Lys - Val - Glu - Val - Ala - Pro - Gly - Tyr - Val - Val -
    61 Thr - Val - Leu - Thr - Trp - Pro - Gly - Thr - Asn - Pro -
    71 Thr - Leu - Ser - Ser - Ile - Leu - Leu - Asn - Ser - His -
    81 Thr - Asp - Val - Val - Pro - Val - Phe - Lys - Glu - HIs -
    91 Trp - Ser - His - Asp - Pro - Phe - Glu - Ala - Phe - Lys -
    101 Asp - Ser - Glu - Gly - Tyr - Ile - Tyr - Ala - Arg - Gly -
    111 Ala - Gln - Asp - Met - Lys - Cys - Val - Ser - Ile - Gln -
    121 Tyr - Leu - Glu - Ala - Val - Arg - Arg - Leu - Lys - Val -
    131 Glu - Gly - His - Arg - Phe - Pro - Arg - Thr - Ile - His -
    141 Met - Thr - Phe - Val - Pro - Asp - Glu - Glu - Val - Gly -
    151 Gly - His - Gln - Gly - Met - Glu - Leu - Phe - Val - Gln -
    161 Arg - Pro - Glu - Phe - His - Ala - Leu - Arg - Ala - Gly -
    171 Phe - Ala - Leu - Asp - Glu - Gly - Ile - Ala - Asn - Pro -
    181 Thr - Asp - Ala - Phe - Thr - Val - Phe - Tyr - Ser - Glu -
    191 Arg - Ser - Pro - Trp - Trp - Val - Arg - Val - Thr - Ser -
    201 Thr - Gly - Arg - Pro - Gly - His - Ala - Ser - Arg - Phe -
    211 Met - Glu - Asp - Thr - Ala - Ala - Glu - Lys - Leu - His -
    221 Lys - Val - Val - Asn - Ser - Ile - Leu - Ala - Phe - Arg -
    231 Glu - Lys - Glu - Trp - Gln - Arg - Leu - Gln - Ser - Asn -
    241 Pro - His - Leu - Lys - Glu - Gly - Ser - Val - Thr - Ser -
    251 Val - Asn - Leu - Thr - Lys - Leu - Glu - Gly - Gly - Val -
    261 Ala - Tyr - Asn - Val - Ile - Pro - Ala - Thr - Met - Ser -
    271 Ala - Ser - Phe - Asp - Phe - Arg - Val - Ala - Pro - Asp -
    281 Val - Asp - Phe - Lys - Ala - Phe - Glu - Glu - Gln - Leu -
    291 Gln - Ser - Trp - Cys - Gln - Ala - Ala - Gly - Glu - Gly -
    301 Val - Thr - Leu - Glu - Phe - Ala - Gln - Lys - Trp - Met -
    311 His - Pro - Gln - Val - Thr - Pro - Thr - Asp - Asp - Ser -
    321 Asn - Pro - Trp - Trp - Ala - Ala - Phe - Ser - Arg - Val -
    331 Cys - Lys - Asp - Met - Asn - Leu - Thr - Leu - Glu - Pro -
    341 Glu - Ile - Met - Pro - Ala - Ala - Thr - Asp - Asn - Arg -
    351 Tyr - Ile - Arg - Ala - Val - Gly - Val - Pro - Ala - Leu -
    361 Gly - Phe - Ser - Pro - Met - Asn - Arg - Thr - Pro - Val -
    371 Leu - Leu - His - Asp - His - Asp - Glu - Arg - Leu - His -
    381 Glu - Ala - Val - Phe - Leu - Arg - Gly - Val - Asp - Ile -
    391 Tyr - Thr - Arg - Leu - Leu - Pro - Ala - Leu - Ala - Ser -
    401 Val - Pro - Ala - Leu - Pro - Ser - Asp - Ser
  3. 아래의 물리화학적 성질을 가진 단백질을 코우드하는 DNA. (1) 분자량 : 45,000±5,000 (2) 등전점 : pI=5.7±0.5 (3)부분 아미노산 배열 : Asp-Ser-Glu-Gly-Tyr-Ile-Tyr-Ala-Gln-Asp-Met-Lys 또는 Gly-His-Trp-Ser-His-Asp-Pro-Phe-Glu을 가짐, (4) 용매에 대한 용해성 : 물, 생리식염수 및 인산완충액에 용해, (5) 생물활성 : 인간의 대장암 유래의 주화 배양 세포인 RPM14788세포(FERM BP-2429)의 전이를 억제하는 활성을 가진, (6) 안정성 : 수용액중에서 pH7.2 및 100℃에서 30분간 방치하면 실활(失活)함. 수용액중에서 pH7.2 및 4℃에서 1개월 방치하여도 안정.
  4. 제3항에 있어서, 실질적으로 아래의 화학식 2로 나타내어지는 염기배열을 가진 DNA.
    화학식 2
    1 ATG ACC AGC AAG GGT CCC GAG GAG GAG CAC
    31 CCA TCG GTG ACG CTC TTC CGC CAG TAC CTG
    61 CGT ATC CGC ACT GTC CAG CCC AAG CCT GAC
    91 TAT GGA GCT GCT GTG GCT TTC TTT GAG GAG
    121 ACA GCC CGC CAG CTG GGC CTG GGC TGT CAG
    151 AAA GTA GAG GTG GCA CCT GGC TAT GTG GTG
    181 ACC GTG TTG ACC TGG CCA GGC ACC AAC CCT
    211 ACA CTC TCC TCC ATC TTG CTC AAC TCC CAC
    241 ACG GAT GTG GTG CCT GTC TTC AAG GAA CAT
    271 TGG AGT CAC GAC CCC TTT GAG GCC TTC AAG
    301 GAT TCT GAG GGC TAC ATC TAT GCC AGG GGT
    331 GCC CAG GAC ATG AAG TGC GTC AGC ATC CAG
    361 TAC CTG GAA GCT GTG AGG AGG CTG AAG GTG
    391 GAG GGC CAC CGG TTC CCC AGA ACC ATC CAC
    421 ATG ACC TTT GTG CCT GAT GAG GAG GTT GGG
    451 GGT CAC CAA GGC ATG GAG CTG TTC GTG CAG
    481 CGG CCT GAG TTC CAC GCC CTG AGG GCA GGC
    511 TTT GCC CTG SAT GAG GGC ATA GCC AAT CCC
    541 ACT GAT GCC TTC ACT GTC TTT TAT AGT GAG
    571 CGG AGT CCC TGG TGG GTG GGG GTT ACC AGC
    601 ACT GGG AGG CCA GGC CAT GCC TCA CGC TTC
    631 ATG GAG GAC ACA GCA GCA GAG AAG CTG CAC
    661 AAG GTT GTA AAC TCC ATC CTG GCA TTC CGG
    691 GAG AAG GAA TGG CAG AGG CTG CAG TCA AAC
    721 CCC CAC CTG AAA GAG GGG TCC GTG ACC TCC
    751 GTG AAC CTG ACT AAG CTA GAG GGT GGC GTG
    781 GCC TAT AAC GTG ATA CCT GCC ACC ATG AGC
    811 GCC AGC TTT GAC TTC CGT GTG GCA CCG GAT
    841 GTG GAC TTC AAG GCT TTT GAG GAG CAG CTG
    871 CAG AGC TGG TGC CAG GCA GCT GGC CAG GGG
    901 GTC ACC CTA GAG TTT GCT CAG AAG TGG ATG
    931 CAC CCC CAA GTG ACA CCT ACT GAT GAC TCA
    961 AAC CCT TGG TGG GCA GCT TTT AGC CGG GTC
    991 TGC AAG GAT ATG AAC CTC ACT CTG GAG CCT
    1021 GAG ATC ATG CCT GCT GCC ACT GAC AAC CGC
    1051 TAT ATC CGC GCG GTG GGG GTC CCA GCT GTA
    1081 GGC TTC TCA CCC ATG AAC CGC ACA CCT GTG
    1111 CTG GTG CAG GAC CAC GAT GAA CGG CTG CAT
    1141 GAG GCT GTG TTC CTC CGT GGG GTG GAC ATA
    1171 TAT ACA CGC CTG CTG CCT GCC CTT GCC AGT
    1201 GTG CCT GCC CTG CCC AGT GAC AGC
  5. (가) 아래의 물리화학적 성질을 가진 단백질의 생산능을 가진 세포를 영양배지에서 배양하여 상기 단백질을 생성시키고, (나) 수득한 배양물로부터 상기 단백질을 회수하는 것을 특징으로 하는 단백질의 제조방법. (1) 분자량 : 45,000±5,000 (2) 등전점 : pI=5.7±0.5 (3)부분 아미노산 배열 : Asp-Ser-Glu-Gly-Tyr-Ile-Tyr-Ala-Gln-Asp-Met-Lys 또는 Gly-His-Trp-Ser-His-Asp-Pro-Phe-Glu을 가짐, (4) 용매에 대한 용해성 : 물, 생리식염수 및 인산완충액에 용해, (5) 생물활성 : 인간의 대장암 유래의 주화 배양 세포인 RPMI4788세포(FERM BP-2429)의 전이를 억제하는 활성을 가짐, (6) 안정성 : 수용액중에서 pH7.2 및 100℃에서 30분간 방치하면 실활(失活)함. 수용액중에서 pH7.2 및 4℃에서 1개월 방치하여도 안정.
  6. 제5항에 있어서, 상기 단백질은 실질적으로 아래의 화학식 1로 나타내어지는 아미노산 배열을 가진 것인 제조방법.
    화학식 1
    1 Met - Thr - Ser - Lys - Gly - Pro - Glu - Glu - Glu - His -
    11 Pro - Ser - Val - Thr - Leu - Phe - Arg - Gln - Tyr - Leu -
    21 Arg - Ile - Arg - Thr - Val - Gln - Pro - Lys - Pro - Asp -
    31 Tyr - Gly - Ala - Ala - Val - Ala - Phe - Phe - Glu - Glu -
    41 Thr - Ala - Arg - Gln - Leu - Gly - Leu - Gly - Cys - Gln -
    51 Lys - Val - Glu - Val - Ala - Pro - Gly - Tyr - Val - Val -
    61 Thr - Val - Leu - Thr - Trp - Pro - Gly - Thr - Asn - Pro -
    71 Thr - Leu - Ser - Ser - Ile - Leu - Leu - Asn - Ser - His -
    81 Thr - Asp - Val - Val - Pro - Val - Phe - Lys - Glu - HIs -
    91 Trp - Ser - His - Asp - Pro - Phe - Glu - Ala - Phe - Lys -
    101 Asp - Ser - Glu - Gly - Tyr - Ile - Tyr - Ala - Arg - Gly -
    111 Ala - Gln - Asp - Met - Lys - Cys - Val - Ser - Ile - Gln -
    121 Tyr - Leu - Glu - Ala - Val - Arg - Arg - Leu - Lys - Val -
    131 Glu - Gly - His - Arg - Phe - Pro - Arg - Thr - Ile - His -
    141 Met - Thr - Phe - Val - Pro - Asp - Glu - Glu - Val - Gly -
    151 Gly - His - Gln - Gly - Met - Glu - Leu - Phe - Val - Gln -
    161 Arg - Pro - Glu - Phe - His - Ala - Leu - Arg - Ala - Gly -
    171 Phe - Ala - Leu - Asp - Glu - Gly - Ile - Ala - Asn - Pro -
    181 Thr - Asp - Ala - Phe - Thr - Val - Phe - Tyr - Ser - Glu -
    191 Arg - Ser - Pro - Trp - Trp - Val - Arg - Val - Thr - Ser -
    201 Thr - Gly - Arg - Pro - Gly - His - Ala - Ser - Arg - Phe -
    211 Met - Glu - Asp - Thr - Ala - Ala - Glu - Lys - Leu - His -
    221 Lys - Val - Val - Asn - Ser - Ile - Leu - Ala - Phe - Arg -
    231 Glu - Lys - Glu - Trp - Gln - Arg - Leu - Gln - Ser - Asn -
    241 Pro - His - Leu - Lys - Glu - Gly - Ser - Val - Thr - Ser -
    251 Val - Asn - Leu - Thr - Lys - Leu - Glu - Gly - Gly - Val -
    261 Ala - Tyr - Asn - Val - Ile - Pro - Ala - Thr - Met - Ser -
    271 Ala - Ser - Phe - Asp - Phe - Arg - Val - Ala - Pro - Asp -
    281 Val - Asp - Phe - Lys - Ala - Phe - Glu - Glu - Gln - Leu -
    291 Gln - Ser - Trp - Cys - Gln - Ala - Ala - Gly - Glu - Gly -
    301 Val - Thr - Leu - Glu - Phe - Ala - Gln - Lys - Trp - Met -
    311 His - Pro - Gln - Val - Thr - Pro - Thr - Asp - Asp - Ser -
    321 Asn - Pro - Trp - Trp - Ala - Ala - Phe - Ser - Arg - Val -
    331 Cys - Lys - Asp - Met - Asn - Leu - Thr - Leu - Glu - Pro -
    341 Glu - Ile - Met - Pro - Ala - Ala - Thr - Asp - Asn - Arg -
    351 Tyr - Ile - Arg - Ala - Val - Gly - Val - Pro - Ala - Leu -
    361 Gly - Phe - Ser - Pro - Met - Asn - Arg - Thr - Pro - Val -
    371 Leu - Leu - His - Asp - His - Asp - Glu - Arg - Leu - His -
    381 Glu - Ala - Val - Phe - Leu - Arg - Gly - Val - Asp - Ile -
    391 Tyr - Thr - Arg - Leu - Leu - Pro - Ala - Leu - Ala - Ser -
    401 Val - Pro - Ala - Leu - Pro - Ser - Asp - Ser
  7. 제5항에 있어서, 상기 세포는 인간 세포, 동물 세포 및 미생물로 된 군으로부터 선택되는 것인 제조방법.
  8. 제7항에 있어서, 인간 세포는 인간의 T세포 백혈병 유래ㅢ 것인 제조방법.
  9. 제8항에 있어서, 인간의 T세포 백혈병 유래의 인간 세포가 HPB-MLT세포(FERM BP-2430) 또는 MOLT-4세포(ATCC CRL 1582)인 제조 방법.
  10. 제5항에 있어서, (가) 단계에는 상기 세포와 상기 단백질을 유발제로서의 칼멧-계량형 소결핵균(BCG)와 리포다당(LPS)을 접촉시키는 단계를 포함하는 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930019832A 1992-09-28 1993-09-27 단백질과이단백질을코우드하는dna및이단백질의제조방법 KR100294977B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28113692A JP3439490B2 (ja) 1992-09-28 1992-09-28 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法
JP92-281136 1992-09-28

Publications (2)

Publication Number Publication Date
KR940007056A true KR940007056A (ko) 1994-04-26
KR100294977B1 KR100294977B1 (ko) 2001-09-17

Family

ID=17634871

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930019832A KR100294977B1 (ko) 1992-09-28 1993-09-27 단백질과이단백질을코우드하는dna및이단백질의제조방법

Country Status (6)

Country Link
US (3) US5498697A (ko)
EP (1) EP0594311B1 (ko)
JP (1) JP3439490B2 (ko)
KR (1) KR100294977B1 (ko)
DE (1) DE69331368T2 (ko)
TW (1) TW241268B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
US6548066B1 (en) 1997-05-12 2003-04-15 Aphton Corporation Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
US6387661B1 (en) * 2001-03-23 2002-05-14 Pe Corporation (Ny) Nucleic acid molecules encoding human aminoacylase proteins
AU2002252456A1 (en) 2001-03-23 2002-10-08 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
WO2003005955A2 (en) * 2001-07-09 2003-01-23 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
CA2520010C (en) * 2003-03-28 2012-07-10 Aphton Corporation Gastrin hormone immunoassays
ES2400058T3 (es) 2004-09-22 2013-04-05 Cancer Advances, Inc. Anticuerpos monoclonales para progastrina
EP3624841A4 (en) 2017-06-15 2021-01-27 Cancer Advances, Inc., COMPOSITIONS AND METHODS OF INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
CN111704658B (zh) * 2018-06-11 2021-11-16 北京市农林科学院 具有消脂护肝功能的毛木耳糖肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925332A (ja) * 1982-08-04 1984-02-09 Mochida Pharmaceut Co Ltd 抗腫瘍性糖蛋白質の製法
JPS60112718A (ja) * 1983-11-21 1985-06-19 Kyorin Pharmaceut Co Ltd 抗腫瘍作用を示す蛋白性物質及びその製造方法
JP2926409B2 (ja) * 1989-05-22 1999-07-28 株式会社林原生物化学研究所 癌転移抑制因子の製造方法

Also Published As

Publication number Publication date
DE69331368D1 (de) 2002-01-31
JPH06107693A (ja) 1994-04-19
US5585474A (en) 1996-12-17
DE69331368T2 (de) 2002-08-08
EP0594311A1 (en) 1994-04-27
JP3439490B2 (ja) 2003-08-25
US5827691A (en) 1998-10-27
KR100294977B1 (ko) 2001-09-17
TW241268B (ko) 1995-02-21
EP0594311B1 (en) 2001-12-19
US5498697A (en) 1996-03-12

Similar Documents

Publication Publication Date Title
KR940007056A (ko) 단백질과 이 단백질을 코우드하는 dna 및 이 단백질의 제조방법
DE69026716D1 (de) Nukleinsäurefragmente von einem genom eines geeigneten mykobakteriums, ihre verwendung zur diagnose von mykobakterieninfektionen sowie diese fragmente enthaltende plasmide
ZA200102385B (en) Nucleotide sequences coding for the dapC gene and process for the production of L-lysine.
EP0326544A4 (en) PRODUCTION OF XANTHANE GUM OBTAINED THROUGH RECOMBINANT DNA.
BR0213779A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
Norris et al. Purification and preliminary crystallographic studies on azurin and cytochrome c′ from Alcaligenes denitrificans and Alcaligenes sp. NCIB 11015
NL8001868A (nl) Verbindingen met antitumor- en antibacterieele werk- zaamheid; werkwijze voor het bereiden daarvan; prepa- raraten met antitumor- en antibacterieele werkzaamheid.
KR920012446A (ko) 병원체-저항식물의 제조방법
CA2062095A1 (en) Process for the genetic manipulation of myxobacteria
EP0668358A1 (en) Antibiotic WAP-8294A, method for preparing the same and antibacterial composition
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
EP0159497B1 (en) Collagenase and production method thereof
KR910014398A (ko) 항생제 데옥시물룬도칸딘, 이의 제조방법 및 약제로서의 이의 용도
EP0084334A1 (en) Polysaccharide substance, process for the production of same, pharmaceutical compositions containing the same and their use as medicaments
JP2594167B2 (ja) 新規抗生物質ｓｆ２６９８物質およびその製造法
US4560748A (en) Streptothricin-group compounds
EP0084333A1 (en) Polysaccharide substance, process for the production of same, pharmaceutical compositions containing the same and their use as medicaments
CN100540669C (zh) 葡萄糖脱氢酶的制造方法
KR860007376A (ko) 인터로이킨-2의 제조방법
JP3530563B2 (ja) Ｋｏ−８１１９物質及びその製造法
Mui et al. Preliminary crystallographic analysis of a complex between tetracycline and the trypsin-modified form of escherichia coli elongation factor tu
KR830001103B1 (ko) 항생물질 sb-72310의 제조방법
Beadle RAF Penrose, Jr., Memorial Lecture. The Gene
JP2990628B2 (ja) 新規植物生長調節物質ａｊｉ−３０２及びその製造法
Caspari Phylogeny: Principles and Methods

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050217

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee